port-77

PORT-77 is an orally bioavailable small molecule inhibitor of the ATP-binding cassette transporter subfamily G member 2 (ABCG2, also known as BCRP). It is under development for the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder characterized by phototoxic skin reactions and progressive liver damage due to accumulation of protoporphyrin IX. Preclinical studies demonstrated that PORT-77 potently inhibits ABCG2 activity *in vitro* and reduces skin phototoxicity and liver damage in mouse models of EPP. The drug has shown favorable safety and pharmacokinetic profiles in early studies, with ongoing phase 1 clinical trials evaluating its safety in healthy volunteers. The originator is Portal Therapeutics, with BridgeBio Pharma also involved in development[1][3][4].